PMN (ProMIS Neurosciences Inc.) stock: $4.16, $37.3M market cap, $53.5M cash, -$16.2M EV, $80.5M fully diluted market cap. Next expected readout: Dec-26. Lead program: PMN310 (Alzheimer Disease, Early Onset), Phase 1. Data from Fully Diluted's biotech stocks database.
What they do
We believe this platform provides a potential advantage by selectively targeting the toxic misfolded proteins with therapeutics. ProMIS’ EpiSelect TM Platform Technology ProMIS’ scientific foundation is centered on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships University of British Columbia (UBC): license to EpiSelect computational algorithm for misfolded-protein modeling
Indications
Alzheimer's disease(Phase 1)
Catalysts
— None
Status note Lead product candidate; antibody selectively targeting toxic misfolded oligomers of amyloid-beta (non-plaque binder). Phase 1b PRECISE-AD trial in Alzheimer's disease; FDA Fast Track designation.
PMN267
Preclinical · ActiveModality: monoclonal antibody
Target misfolded TDP-43
Partnerships Collaboration with a partner with expertise in vectorization for intracellular delivery
Indications
Amyotrophic lateral sclerosis (ALS)(Preclinical)
Status note Second lead product candidate, targeting TDP-43-associated ALS (misfolded TDP-43).
PMN442
Preclinical · ActiveModality: monoclonal antibody
Target misfolded alpha-synuclein
Indications
Dementia with Lewy bodies (DLB)(Preclinical)
Parkinson's disease(Preclinical)
Multiple system atrophy (MSA)(Preclinical)
Status note Selected lead candidate for synucleinopathies (DLB, PD, MSA), selectively targeting pathogenic forms of alpha-synuclein.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.